CX3CR1 and atherosclerosis: While CX3CL1 and CX3CR1 are expressed at low levels in healthy vessels, their expression increases significantly under pathological conditions [12, 13], and pharmacological inhibition of CX3CR1 (the CX3CR1 antagonist F1) has been reported to reduce atherosclerosis [14].